A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Conditions: Gout Arthritis Interventions: Drug: Recombinant Anti-IL-1 β Humanized Monoclonal Antibody Injection 100 mg; Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg; Drug: Colchicine 0.5 mg Sponsors: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06270225

Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials